Atomwise

Website

Atomwise Inc.

19 Investors
Pharmaceutical Technology
SAN FRANCISCO, CA

Atomwise Inc. is a pioneering technology-enabled pharmaceutical company that employs artificial intelligence to transform the landscape of small molecule drug discovery. By leveraging advanced machine learning techniques, Atomwise aims to streamline the drug development process, making it not only more efficient but also more effective in identifying viable therapeutic candidates.

Products & Team

AtomNet

Drug DiscoverySeed

AtomNet is an advanced AI-powered drug discovery platform that utilizes deep learning algorithms and convolutional neural networks to predict interactions between small molecules and protein targets. This cutting-edge technology enables the virtual screening of billions of chemical compounds, rapidly identifying the most promising candidates for further development.

Value Proposition

AtomNet addresses the inefficiencies of traditional drug discovery methods by accelerating the identification of effective drug candidates, thus significantly reducing both the time and costs involved in the drug development process.

Pain Points

Traditional drug discovery processes are often slow, costly, and suffer from low success rates when it comes to developing new therapeutics. Atomwise addresses these challenges by providing a faster and more efficient alternative.

Rapid virtual screening of billions of compoundsPredictive modeling of molecule-protein binding affinitiesDeep learning and convolutional neural network technologySupport for a wide range of therapeutic areas
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
SAN FRANCISCO, CA
Primary headquarters

Funding History

Total Raised:
$44.3M
E

Equity, Other Offering

March 2024
$50.0M
Target
Progress
89%
Raised
$44.3M
Target
$50.0M
#000173615325000001